Cost comparison of IV vs subcutaneous trastuzumab in HER2+ breast cancer in Morocco

Disparities in mammogram screening amongst LGBTQ+ populations

AI improves accuracy in identifying HER2-low and HER2-ultralow breast cancers

Trastuzumab deruxtecan plus pertuzumab may delay cancer growth for some HER2-positive advanced breast cancers

HER2-positive breast cancer: Predicting pCR from clinicopathologic variables and genomic testing

Oral paclitaxel shows non-inferior efficacy compared to IV paclitaxel for HER2-negative mBC

CtDNA monitoring of ER+/HER2- breast cancer during adjuvant endocrine therapy shows promise

Vepdegestrant could extend PFS for some ESR1-mutated advanced breast cancers

Olaparib boosts chemotherapy’s impact on BRCA-mutated breast cancer

Intraoperative radiotherapy: The Medical City experience

The added value of integrative medicine

Boost IORT in breast cancer: Peruvian experience